» Articles » PMID: 26256147

Current Methods for the Identification of Carbapenemases

Overview
Journal J Chemother
Date 2015 Aug 11
PMID 26256147
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Detection of carbapenemases in clinical microbiology labs is a challenging issue. Comparison of the results of susceptibility testing with the breakpoint values of carbapenems is the first step in the screening of carbapenemase producers. To date, screening of carbapenemase-producing (CP) bacteria has been mostly performed by a selective medium. Although these media are practical for the detection of most CP isolates, the inoculated plates have to be incubated overnight. Subsequently, we need the confirmation of the carbapenemase producers present in the culture medium by additional testing [e.g. inhibition studies with liquid or solid media, modified Hodge test (MHT), or gradient strips], which can take up to another 48 hours. Despite the lack of discrimination between the three different classes of carbapenemases (KPC, MBL and OXA) and difficulties in the interpretation of the results, the MHT is usually deemed as the phenotypic reference method for the confirmation of carbapenemase production. Molecular techniques, such as real-time polymerase chain reaction (PCR) assays, in contrast to phenotypic methods that are very time consuming, are faster and allow for the quick identification of carbapenemase genes. These techniques can detect and characterize carbapenemases, including NDM- and KPC-mediated resistance, which is critical for epidemiological investigations. The aim of this review is to gather a summary of the available methods for carbapenemase detection and describe the strengths and weaknesses of each method.

Citing Articles

Rapid Simultaneous Detection of the Clinically Relevant Carbapenemase Resistance Genes KPC, OXA48, VIM and NDM with the Newly Developed Ready-to-Use qPCR CarbaScan LyoBead.

Reinicke M, Diezel C, Teimoori S, Haase B, Monecke S, Ehricht R Int J Mol Sci. 2025; 26(3).

PMID: 39940986 PMC: 11818240. DOI: 10.3390/ijms26031218.


Role of CRISPR-Cas systems and anti-CRISPR proteins in bacterial antibiotic resistance.

Kadkhoda H, Gholizadeh P, Kafil H, Ghotaslou R, Pirzadeh T, Rezaee M Heliyon. 2024; 10(14):e34692.

PMID: 39149034 PMC: 11325803. DOI: 10.1016/j.heliyon.2024.e34692.


Velen. Methanolic Extract: In Vitro and In Silico Screening of Its Antimicrobial, Antioxidant, Anti-Quorum Sensing, Antibiofilm, and Anticancer Activities.

Noumi E, Ahmad I, Bouali N, Patel H, Ghannay S, ALrashidi A Life (Basel). 2023; 13(1).

PMID: 36676011 PMC: 9862435. DOI: 10.3390/life13010062.


Antibiotic therapy for pan-drug-resistant infections.

Ozma M, Abbasi A, Asgharzadeh M, Pagliano P, Guarino A, Kose S Infez Med. 2022; 30(4):525-531.

PMID: 36482958 PMC: 9715010. DOI: 10.53854/liim-3004-6.


Evaluation of phenotypic detection of carbapenemase-producing Pseudomonas spp. from clinical isolates.

de Oliveira Santos I, da Conceicao Neto O, Santos da Costa B, Tavares Teixeira C, da Silva Pontes L, Silveira M Braz J Microbiol. 2022; 54(1):135-141.

PMID: 36327041 PMC: 9943810. DOI: 10.1007/s42770-022-00857-4.